Exagen prices public offering of 3.35M shares at $5.25/share for ~$17.6M gross proceeds

EXAGEN INC.

3,350,000 shares priced at $5.25; gross proceeds $17.6M; net expected ~$16.2M after expenses.
Underwriter Canaccord Genuity has a 30-day option to buy up to 502,500 additional shares.
Offering expected to close May 9, 2025; proceeds for working capital and general corporate purposes.
All shares sold by Exagen; no binding acquisition agreements at this time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.